Lipistad (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. This reduction in hepatic cholesterol triggers an increase in LDL‑receptor expression, enhancing clearance of LDL particles from the bloodstream and thereby lowering plasma cholesterol levels.

The appropriate dose of Lipistad is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, age, and tolerance. Typical starting doses range from low to moderate strengths, with adjustments made as needed under medical supervision.

Atorvastatin is contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception while on therapy. Use during breastfeeding is not recommended, as the drug may be excreted in breast milk.

To order Lipistad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipistad (atorvastatin) is a high‑potency statin with a long half‑life, allowing once‑daily dosing and substantial LDL‑cholesterol reductions. Compared with lower‑intensity statins such as pravastatin, atorvastatin often achieves greater lipid lowering at comparable doses, but individual response and tolerability guide the choice of therapy.

Store Lipistad tablets at temperatures below 25 °C in their original container. Protect them from moisture, excessive heat and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Lipistad is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the dose without medical advice.

The most serious adverse events include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and significant liver injury indicated by marked elevations in transaminases. Prompt medical attention is required if patients experience unexplained muscle pain, weakness, dark urine, or jaundice.

Lipistad should not be used by individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to atorvastatin or any excipients, pregnant women, or those who are breastfeeding. Caution is also advised for patients with a history of muscle disorders.